Romanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

polymyositis/cefalee

Linkul este salvat în clipboard
ArticoleStudii cliniceBrevete
9 rezultate

Cluster headache or giant cell arteritis?

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
We describe an elderly female patient with known polymyositis who presented with new onset temporal headache that was diagnosed as giant cell arteritis but subsequently had a typical clinical course of cluster headache. This case illustrates the potential for diagnostic confusion between giant cell

Varicella zoster encephalitis in an immunocompromised patient presented with migraine type headache: A case report.

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
Varicella zoster virus (VZV) has been increasingly linked with encephalitis and atypical presentations in immunosuppressed patients. We present a patient with history of immunosuppressant intake for polymyositis who initially presented with throbbing frontal headache that raised the suspicion of

Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
Purpose: Selexipag is an oral nonprostanoid IP prostacyclin receptor agonist that is indicated for treatment of pulmonary arterial hypertension (PAH). In patients with continued symptoms of PAH despite maximized oral therapy with

Complications of intravenous immune globulin treatment in neurologic disease.

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
Intravenous immune globulin (IVIg) is advocated as a safe treatment for immune-mediated neurologic disease. We reviewed the medical records of 88 patients who were given IVIg for a neurologic illness. Major complications in four patients (4.5%) included congestive heart failure in a patient with

Chronic meningococcal meningitis. An association with C5 deficiency.

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
A 44-year-old man with a history of presumed meningococcal meningitis 32 years before, presented with a three-month illness, characterized by fever, 13.5-kg (30-lb) weight loss, occipital headache, shoulder pain, and muscle weakness, which had been diagnosed as "polymyositis" and treated

[Toxoplasmosis and dermatomyositis: a causal or casual relationship?].

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
A case of a 10 year old girl with typical clinical, cutaneous and muscular picture of dermatomyositis and positive serological investigation for toxoplasmosis with neurological complications (hemiparesis and headache) is reported. In literature several case reports have suggested an association

Intravenous immune globulin therapy for neurologic diseases.

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
High-dose intravenous immune globulin (IVIg) has emerged as an important therapy for various neurologic diseases. Different interpretations of clinical trial results; the expected benefit of IVIg compared with that of alternate therapies; and issues about IVIg's safety, cost, and mechanisms of

Therapy with intravenous immunoglobulins: complications and side-effects.

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
Therapy with intravenous immunoglobulins (IVIG) is thought to be a safe treatment for a number of immune-mediated neurological diseases. Published data about prevalence of adverse effects range from 11 to 81%. The purpose of our study was to present a representative view on adverse effects by

Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
Subcutaneous immunoglobulin (SCIg) therapy is indicated in primary and secondary immunodeficiency diseases. Its use in practice is being extended to autoimmune diseases. Few studies investigated the feasibility and safety of SCIg in these rare conditions. The aim was to describe the use of SCIg in
Alăturați-vă paginii
noastre de facebook

Cea mai completă bază de date cu plante medicinale susținută de știință

  • Funcționează în 55 de limbi
  • Cure pe bază de plante susținute de știință
  • Recunoașterea ierburilor după imagine
  • Harta GPS interactivă - etichetați ierburile în locație (în curând)
  • Citiți publicațiile științifice legate de căutarea dvs.
  • Căutați plante medicinale după efectele lor
  • Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate

Google Play badgeApp Store badge